<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699543</url>
  </required_header>
  <id_info>
    <org_study_id>ECO-PLEASANT</org_study_id>
    <nct_id>NCT00699543</nct_id>
  </id_info>
  <brief_title>The Efficacies of The New Paclitaxel-Eluting CoroflexTM Please Stent in Percutaneous Coronary Intervention</brief_title>
  <official_title>The Efficacies of The New Paclitaxel-Eluting CoroflexTM Please Stent in Percutaneous Coronary Intervention: Comparison or Efficacy Between COroflex PLEASe ANd TaxusTM Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives&#xD;
&#xD;
      : To evaluate the clinical efficacy, angiographic outcomes, and safety of the new&#xD;
      paclitaxel-eluting coronary stent (CoroflexTM Please, B Braun, Germany), compared with&#xD;
      another paclitaxel-eluting coronary stent system (TaxusTM, Boston Scientific, USA) in the&#xD;
      treatment of coronary stenosis.&#xD;
&#xD;
      Study Design&#xD;
&#xD;
      : Prospective, open label, 2: 1 randomized multi-center trial. Patients will be randomized&#xD;
      according to the type of drug eluting stent ( CoroflexTM Please vs. TaxusTM). Randomization&#xD;
      will also be stratified per hospital for the presence of DM and the presence of long lesions&#xD;
      (lesion length &gt; 28mm)&#xD;
&#xD;
      Patient Enrollment&#xD;
&#xD;
      :915 patients enrolled at 13 centers in Korea.&#xD;
&#xD;
      Patient Follow-Up&#xD;
&#xD;
      :Clinical follow-up will occur at 1, 4, 9, 12 months and 2, 3years after intervention.&#xD;
      Investigator or designee may conduct follow-up as telephone contacts or office visits.&#xD;
&#xD;
      Primary Endpoint&#xD;
&#xD;
      :Clinically driven Target vessel Revascularization (TVR) at 9 months.&#xD;
&#xD;
      Secondary Endpoints&#xD;
&#xD;
      :A. Clinical safety and efficacy end points&#xD;
&#xD;
        1. Major Cardiac Adverse Events (MACE; All Death, cardiac death, Myocardial infarction&#xD;
           (Q-wave and non-Q wave), TVR)&#xD;
&#xD;
        2. Target Vessel Failure (TVF; cardiovascular death, myocardial infarction, clinically&#xD;
           driven TVR)&#xD;
&#xD;
        3. Stent thrombosis&#xD;
&#xD;
      B. Angiographic efficacy end points&#xD;
&#xD;
        1. in-stent binary restenosis by QCA&#xD;
&#xD;
        2. in-stent and in-lesion late loss by QCA&#xD;
&#xD;
        3. in-stent and in-lesion MLD and percentage diameter stenosis by QCA immediately after the&#xD;
           index procedure and at 9 months of follow-up&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically driven Target vessel Revascularization (TVR)</measure>
    <time_frame>9 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Cardiac Adverse Events (MACE; All Death, cardiac death, Myocardial infarction (Q-wave and non-Q wave), TVR)</measure>
    <time_frame>1, 4, 9, 12 months and 2, 3years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF; cardiovascular death, myocardial infarction, clinically driven TVR)</measure>
    <time_frame>1, 4, 9, 12 months and 2, 3years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1, 4, 9, 12 months and 2, 3years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent binary restenosis by QCA</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-lesion late loss by QCA</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-lesion MLD and percentage diameter stenosis by QCA</measure>
    <time_frame>Immediately after the index procedure and at 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">915</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coroflex Please stent implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taxus stent implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coroflex Please stent implantation</intervention_name>
    <description>Use Coroflex Please stent in the treatment of coronary stenosis</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Coroflex Please stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Taxus stent implantation</intervention_name>
    <description>Use Taxus stent in the treatment of coronary stenosis</description>
    <arm_group_label>T</arm_group_label>
    <other_name>Taxus stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  General Inclusion Criteria&#xD;
&#xD;
               1. Subject must be at least 18 years of age.&#xD;
&#xD;
               2. Subject is able to verbally confirm understandings of risks, benefits and&#xD;
                  treatment alternatives of receiving the CoroflexTM Please stent and he/she or&#xD;
                  his/her legally authorized representative provides written informed consent prior&#xD;
                  to any study related procedure.&#xD;
&#xD;
               3. Subject must have coronary artery stenosis (&gt;50% by visual estimate) with&#xD;
                  evidence of myocardial ischemia (e.g., stable, unstable angina, myocardial&#xD;
                  infarction, silent ischemia, positive functional study or a reversible changes in&#xD;
                  the electrocardiogram (ECG) consistent with ischemia.) or Subject must have&#xD;
                  significant coronary artery stenosis (&gt;70% by visual estimate)&#xD;
&#xD;
          -  Angiographic Inclusion Criteria&#xD;
&#xD;
               1. Target lesion(s) must be located in a native coronary artery with visually&#xD;
                  estimated diameter of ≥ 2.5 mm and ≤ 4.0 mm.&#xD;
&#xD;
               2. Target lesion(s) must be amenable for percutaneous coronary intervention&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  General Exclusion Criteria&#xD;
&#xD;
               1. The patient has a known hypersensitivity or contraindication to any of the&#xD;
                  following medications:&#xD;
&#xD;
                    -  Heparin&#xD;
&#xD;
                    -  Aspirin&#xD;
&#xD;
                    -  Both Clopidogrel and Ticlopidine&#xD;
&#xD;
                    -  Paclitaxel&#xD;
&#xD;
                    -  Stainless steel&#xD;
&#xD;
                    -  Contrast media(*) (*)Patients with documented sensitivity to contrast media&#xD;
                       which can be effectively pre-medicated with steroids and diphenhydramine&#xD;
                       [e.g. rash] may be enrolled. Those with true anaphylaxis to prior contrast&#xD;
                       media, however, should not be enrolled.&#xD;
&#xD;
               2. Systemic (intravenous) Paclitaxel use within 12 months.&#xD;
&#xD;
               3. Female of childbearing potential, unless a recent pregnancy test is negative, who&#xD;
                  possibly plan to become pregnant any time after enrollment into this study.&#xD;
&#xD;
               4. History of bleeding diathesis or known coagulopathy (including heparin- induced&#xD;
                  thrombocytopenia), or will refuse blood transfusions.&#xD;
&#xD;
               5. Gastrointestinal or genitourinary bleeding within the prior 3 months, or major&#xD;
                  surgery within 2 months.&#xD;
&#xD;
               6. An elective surgical procedure is planned that would necessitate interruption of&#xD;
                  thienopyridines during the first 6 months post enrollment.&#xD;
&#xD;
               7. Non-cardiac co-morbid conditions are present with life expectancy &lt;1 year or that&#xD;
                  may result in protocol non-compliance (per site investigator's medical judgment).&#xD;
&#xD;
               8. Patients who are actively participating in another drug or device investigational&#xD;
                  study, which have not completed the primary endpoint follow-up period.&#xD;
&#xD;
               9. Patients with LVEF&lt;25% or those with cardiogenic shock&#xD;
&#xD;
              10. Patients with acute ST elevation myocardial infarction who requires primary PCI&#xD;
&#xD;
              11. Patients with acute ST elevation myocardial infarction within 48hrs&#xD;
&#xD;
              12. Creatinine level ≥ 3.0mg/dL or dependence on dialysis.&#xD;
&#xD;
          -  Angiographic Exclusion Criteria&#xD;
&#xD;
               1. Patients with significant left main stem stenosis which requires&#xD;
                  revascularization therapy&#xD;
&#xD;
               2. Patients who's target lesion has in-stent restenosis at the stented segment of&#xD;
                  drug-eluting stents or bare metal stents&#xD;
&#xD;
               3. Target lesions with bifurcating disease which require side branch stenting&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Soo Kim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>In-Ho Chae, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seung-Ho Hur, MD, Ph</last_name>
    <role>Study Chair</role>
    <affiliation>Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae-Jin Youn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soo-Joong Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyunghee University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keum-Soo Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byung-Ok Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University Sang-gye Paik Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Min-Su Hyon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soon Chun Hyang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Wook Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong-Seon Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yeungnam University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Doo-Il Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae-Joon Cha, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kosin University Gospel Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Gon Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ulsan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hee-Kyoung Jeon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uijeongbu St. Mary's Hospital</affiliation>
  </overall_official>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>June 16, 2008</study_first_submitted>
  <study_first_submitted_qc>June 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2008</study_first_posted>
  <last_update_submitted>December 15, 2013</last_update_submitted>
  <last_update_submitted_qc>December 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2013</last_update_posted>
  <responsible_party>
    <name_title>Hyo-Soo, Kim</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

